Eupraxia Pharmaceuticals (EPRX) stock

Extended-release medicines , market cap $436M

Extended-release medicines

Worth $436M

$7.63

+2.83%

As of Tuesday's close · Live for Pro members at the open

Quality Score

-1

Poor

In its industry

#151of 281

Biotech

Checks firing

3of 14

Choppy

From 52-week high

-18.1%

under its best in a year

EPRX's Quality Score fell 1 point on Tue, Nov 10, to -1.

Follow EPRX's trial news. Pro members can get an alert when Eupraxia Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when EPRX files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextDec 2026“The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.”Trial data · SEC filing · Oct 15

Key facts on EPRX

Key facts on EPRX
Holding it back	30.5% more shares than a year ago from Massive's market data
Latest filing	6-K, Sep 30 Issued a release: "Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis"

1 more reason behind EPRX's -1, free with an account →3 more reasons behind EPRX's -1, for Pro members.

EPRX in the news

After hoursEupraxia Pharmaceuticals Establishes At-The-Market Offering Program GlobeNewswire and 5 more

EPRX catalysts

Coming up

What's next for EPRX, and how long its cash lasts

Next step the company has named

Dec 2026“The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.”Trial data · SEC filing · Oct 15

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: RESOLVEPhase 1/2 · Recruiting · 117 people · main data estimated Dec 2026 · NCT05608681

For Pro members: 1 more milestone and 88 filings.

Cash runway Dec 31, 2025 balance sheet

$80.6M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into the second half of 2028” (8-K, Aug 11).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

For Pro members: every trade.

Get an alert when EPRX files news on its trialA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why EPRX scores -1

Poorfor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

+3Chart checks 3 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
News subtracts

No effect today: Run-up, Size, Growth, Cash flow, and Persistence.

What every line is worth, and the reason behind it, on EPRX and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:56 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when EPRX's Quality Score turns up

A free account. No card.

How EPRX ranks in Biotech

EPRX is #151 of 281 by Quality Score.

How EPRX ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	ELDNEledon Pharmaceuticals		Open for its score
	ENTXEntera Bio		Open for its score
	ETRAElectra Therapeutics		Open for its score
151	EPRXEupraxia Pharmaceuticals	3/14	-1

EPRX sales and profit by year

Profit by year

Sales fell every year from 2023 to 2025, to $0. It lost money in each of the three years.

EPRX has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on EPRX, and all 14 on every stock.Get in free →

EPRX RSI today: 56.1, above its 50-day and 200-day averages

Not scored

RSI 56.1, MACD above signal, above both averages. Not scored.13 readings

The deep dive on EPRX

What it does and how it makes money1 findingFor Pro members1 finding on what EPRX does and how it makes money, for Pro members
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades EPRX, for Pro members

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

49 employeeseupraxiapharma.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on EPRX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn EPRX's score around: 7 things
4 more filings explained, a plain line each
Real-⁠time prices, no delay

See EPRX's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: EPRX's Quality Score is -1 (Poor), #151 of 281 in Biotech.

What does EPRX's Quality Score say?

EPRX scores -1 today, which Breakaway calls Poor. It is #151 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Shares: 17.8% more than a year ago (to Dec 31). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is EPRX's Quality Score?

EPRX scores -1 today, which Breakaway calls Poor (below zero). That is #151 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind EPRX's -1.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.